Pharmaceuticals

CCHT

CCHT released FY2025 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 2.277 B (forecast CNY 4.364 B), actual EPS CNY -2.6272

CCHT released FY2026 Q1 earnings on April 21 During-Market (BJT), actual revenue CNY 2.587 B, actual EPS CNY 0.69

CCHT released FY2025 annual earnings on April 21 After-Market BJT, actual revenue CNY 12.08 B (forecast CNY 13.98 B), actual EPS CNY 0.39 (forecast CNY 5.15)

CCHT to Release FY2026 Q1 Earnings on April 22 During-Market (BJT)

CCHT to Release FY2025 Annual Earnings on March 12, 2026 After-Market (BJT), Forecast Revenue CNY 13.8 B, EPS CNY 5.27

CCHT released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 3.204 B (forecast CNY 5.071 B), actual EPS CNY 0.4556

CCHT released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 9.807 B, actual EPS CNY 2.8959

CCHT to Release FY2025 Q3 Earnings on October 31 After-Market (BJT), Forecast Revenue CNY 5.071 B

CCHT released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 3.605 B (forecast CNY 3.809 B), actual EPS CNY 1.2703

CCHT released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), actual revenue CNY 6.603 B, actual EPS CNY 2.44

CCHT to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Brillian Pharma INC.'s Amlodipine Besylate Oral Solution Lyophilized Powder Approved by FDA

Shenzhen Changgang New Private Equity Fund Management Co., Ltd. Established

Changchun High-Tech Saw First Double-Digit Decline in 2024

Changchun High-Tech Announces H-Share Listing and Approval of Innovative Drug

Changchun High-Tech's Subsidiary New Drug Approval Boosts Stock Price

China 银河 Analyst Gives Changchun High New Buy Rating

Changchun High-Tech Approved for Class 1 Innovative Drug Jinbeixin

Jinsai Pharmaceutical's Fuxin Qibai Monoclonal Antibody Approved for Market

Changchun High-Tech Initiates Hong Kong Listing Preparations

Ordinary dividend (cash)

Ex Date: 2026.05.25, Cash dividend 0.16 CNY

000661

Changchun High-tech's subsidiary, GenSci Pharmaceuticals, has received FDA orphan drug designation for GenSci128, a new chemical drug targeting gastric cancer. GenSci128 is a selective reactivator for the TP53 Y220C mutation, aimed at treating advanced solid tumors, including pancreatic, gastric, ovarian, breast, and colorectal cancers. It falls under the U.S. new drug registration category '505b1.'

CoinLive

Changchun High-tech Subsidiary Receives FDA Orphan Drug Designation for GenSci128, Targeting Gastric Cancer

Changchun High-Tech's subsidiary, Changchun GeneScience Pharmaceuticals, has received orphan drug designation from the U.S. FDA for GenSci128, aimed at treating pancreatic cancer. This designation is a crucial advancement for the company, offering benefits like market exclusivity and potential tax credits to support the drug's development and commercialization.

GenSci128 Receives Orphan Drug Designation for Pancreatic Cancer Treatment

CCHT's subsidiary Changchun Jinsai Pharmaceutical's clinical trial application for GenSci141 ointment has been approved, aimed at improving the issue of small penises in children. This is the world's first drug targeting this problem, and the market is highly concerned about the clinical progress of this project. CCHT stated that the project is still in the early stages, and there is currently no information available for external communication

Wallstreetcn

CCHT's "New Drug for Treating Male Children's Developmental Disorders" Sparks Stock Price Surge; Company Responds: Project is Still in Early Stages

Changchun Pharmaceutical's subsidiary, GenSci098, received a $70 million upfront payment for an external licensing deal, as well as $50 million in recent development milestone payments, with a potential total of $1.365 billion in milestone payments and a 10% sales commission on net sales

"Northeast Medicine Mogul" Transforms into Innovative Pharmaceuticals

600415

002643

002864

On November 4th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 157 million yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Changchun Gaoxin 000661 Equity Incentive Restricted Circulation 42,900 Yunnai Power 000903 Equity Incentive Restricted Circulation 14,978,800 YIWU CCC 600415 Equity Incentive Restricted Circulation 795,600 Valiant 002643 Equity Incentive Restricted Circulation 7,128,800 Panlong Pharmaceutical 002864 Equity Incentive Restricted Circulation 281,600

Zhitong

YIWU CCC

Valiant

Panlong Pharmaceutical

Zhitong A-share lock-up release overview | November 4

CCHT's subsidiary, GenSci Pharmaceutical, has received approval from the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci134 injection. This drug is a biological product for the treatment of growth hormone deficiency, suitable for adult and pediatric patients, especially for those with idiopathic short stature

CCHT: GenSci134 injection domestic production drug registration clinical trial application approved

CCHT's subsidiary Changchun Jinsai Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for the injectable GenSci143. This drug is a Class 1 biological product primarily used for the treatment of advanced solid tumors such as prostate cancer and lung cancer, with dual potential for targeted chemotherapy and tumor immunotherapy, aimed at overcoming tumor heterogeneity and resistance

CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drug

CCHT announced that the company decided to repurchase a portion of A shares through centralized bidding trading in November 2024, for the purpose of equity incentives or employee stock ownership plans, with a planned repurchase fund of 300 million to 500 million yuan, and the repurchase price not exceeding 160 yuan per share. As of October 31, 2025, the company had cumulatively repurchased 3.8945 million shares, accounting for 0.95% of the total share capital, with a highest transaction price of 112.25 yuan per share, a lowest transaction price of 84 yuan per share, and a transaction amount of 399 million yuan. The company will continue to repurchase according to the plan and disclose timely updates

CCHT: Accumulated nearly 400 million yuan to repurchase company shares for incentives

CCHT(000661.SZ)